MeiraGTx's Three-Year Data From Completed Phase 1 AQUAx Study Of AAV-hAQP1 For Grade 2/3 Late Radiation-Induced Xerostomia Shows Meaningful Improvements In Symptoms
Benzinga Newsdesk 6 months ago
BiotechHealth CareGeneral
Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts.Increases in
- Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts.
- Increases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 years.
- AAV-hAQP1 was safe and well tolerated at each dose tested